Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
BMJ Open. 2021 Dec 7;11(12):e054479. doi: 10.1136/bmjopen-2021-054479.
Suicide is a serious problem worldwide and 90% cases are associated with pre-existing or underlying mental illness. As a common treatment for depressive symptoms that suicidal people may receive, selective serotonin reuptake inhibitors (SSRIs) have been linked to a possible increase in suicide rates. Studies focusing on SSRIs and suicide have produced inconsistent results, suggesting that use of SSRIs decreases, increases, has no effect on suicide rates, or that the effect of SSRIs on suicide is age-dependent. This protocol of network meta-analysis aims to precisely evaluate the time effects of SSRIs by observing weekly changes of suicidality in the first 2 months of the treatment, and consequently, to explore whether the effect of the SSRIs on suicide varies depending on the stages of the treatment; if so, we will identify the turning point.
We will search in the following databases: PubMed, Web of science, China National Knowledge Infrastructure and Wanfang Data, from dates of inception to 9 July 2021, with language restricted to English and Chinese. Studies focusing on the time effect of SSRIs on suicide will be retrieved. Then, the study selection process will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline, and the quality assessment will be conducted with Cochrane Collaboration's tool. Two researchers will work independently on data extraction using a standardised data extraction spreadsheet. Any disagreement between two researchers will be discussed and determined by a third researcher.
This work does not require ethics approval as it will be based on published studies. This review will be published in peer-reviewed journals.
CRD42021244779.
自杀是一个全球性的严重问题，其中 90%的案例与先前存在或潜在的精神疾病有关。选择性 5-羟色胺再摄取抑制剂（SSRIs）作为一种常见的治疗自杀人群抑郁症状的方法，与自杀率可能增加有关。关注 SSRIs 和自杀的研究结果不一致，表明 SSRIs 的使用可能会降低、增加、对自杀率没有影响，或者 SSRIs 对自杀的影响取决于年龄。本网络荟萃分析方案旨在通过观察治疗前 2 个月内每周自杀意念的变化，精确评估 SSRIs 的时间效应，并据此探讨 SSRIs 对自杀的影响是否取决于治疗阶段；如果是这样，我们将确定转折点。
我们将在以下数据库中进行检索：PubMed、Web of Science、中国知网和万方数据，检索时间从建库开始到 2021 年 7 月 9 日，语言限制为英语和中文。我们将检索关注 SSRIs 对自杀的时间效应的研究。然后，研究选择过程将遵循系统评价和荟萃分析的首选报告项目指南，并使用 Cochrane 协作工具进行质量评估。两名研究人员将使用标准化的数据提取电子表格独立进行数据提取。如果两名研究人员之间存在分歧，将进行讨论并由第三名研究人员确定。
本研究不需要伦理批准，因为它将基于已发表的研究。本综述将发表在同行评议的期刊上。
PROSPERO 注册号：CRD42021244779。
